EGFR and non-small cell lung carcinoma: In conclusion, our results suggest that increased copy number of the HER3 gene does not significantly enhance gefitinib sensitivity in EGFR+ NSCLC patients, therefore HER3 FISH is not likely to be useful for selection of NSCLC patients for TKI therapy.